Everolimus in diffuse large B-cell lymphomas

Michele Merli, Andrea Ferrario, Margherita Maffioli, Luca Arcaini, Francesco Passamonti

Research output: Contribution to journalArticle

Abstract

Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell cycle arrest and is synergistic with rituximab. Phase I studies indicated 10 mg daily to be the best dosing of everolimus in DLBCL. A large Phase II study in relapsed/refractory DLBCL confirmed the substantial activity (overall response rate: 30%) and good tolerability of everolimus in DLBCL, with thrombocytopenia being the main toxicity. The combination of everolimus and rituximab showed encouraging results (objective response rate: 38%; complete response: 13%), without increasing toxicity. Combination studies of everolimus with novel agents or with immunochemotherapy are underway.

Original languageEnglish
Pages (from-to)373-383
Number of pages11
JournalFuture Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cell Cycle Checkpoints
Thrombocytopenia
Everolimus
Phosphotransferases
Cell Line

Keywords

  • diffuse large B-cell lymphoma
  • everolimus
  • mTOR pathway
  • rapamycin analogs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Merli, M., Ferrario, A., Maffioli, M., Arcaini, L., & Passamonti, F. (2015). Everolimus in diffuse large B-cell lymphomas. Future Oncology, 11(3), 373-383. https://doi.org/10.2217/fon.14.264

Everolimus in diffuse large B-cell lymphomas. / Merli, Michele; Ferrario, Andrea; Maffioli, Margherita; Arcaini, Luca; Passamonti, Francesco.

In: Future Oncology, Vol. 11, No. 3, 01.02.2015, p. 373-383.

Research output: Contribution to journalArticle

Merli, M, Ferrario, A, Maffioli, M, Arcaini, L & Passamonti, F 2015, 'Everolimus in diffuse large B-cell lymphomas', Future Oncology, vol. 11, no. 3, pp. 373-383. https://doi.org/10.2217/fon.14.264
Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F. Everolimus in diffuse large B-cell lymphomas. Future Oncology. 2015 Feb 1;11(3):373-383. https://doi.org/10.2217/fon.14.264
Merli, Michele ; Ferrario, Andrea ; Maffioli, Margherita ; Arcaini, Luca ; Passamonti, Francesco. / Everolimus in diffuse large B-cell lymphomas. In: Future Oncology. 2015 ; Vol. 11, No. 3. pp. 373-383.
@article{33ca607ead864678a7dcb8dce8aaae54,
title = "Everolimus in diffuse large B-cell lymphomas",
abstract = "Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell cycle arrest and is synergistic with rituximab. Phase I studies indicated 10 mg daily to be the best dosing of everolimus in DLBCL. A large Phase II study in relapsed/refractory DLBCL confirmed the substantial activity (overall response rate: 30{\%}) and good tolerability of everolimus in DLBCL, with thrombocytopenia being the main toxicity. The combination of everolimus and rituximab showed encouraging results (objective response rate: 38{\%}; complete response: 13{\%}), without increasing toxicity. Combination studies of everolimus with novel agents or with immunochemotherapy are underway.",
keywords = "diffuse large B-cell lymphoma, everolimus, mTOR pathway, rapamycin analogs",
author = "Michele Merli and Andrea Ferrario and Margherita Maffioli and Luca Arcaini and Francesco Passamonti",
year = "2015",
month = "2",
day = "1",
doi = "10.2217/fon.14.264",
language = "English",
volume = "11",
pages = "373--383",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Everolimus in diffuse large B-cell lymphomas

AU - Merli, Michele

AU - Ferrario, Andrea

AU - Maffioli, Margherita

AU - Arcaini, Luca

AU - Passamonti, Francesco

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell cycle arrest and is synergistic with rituximab. Phase I studies indicated 10 mg daily to be the best dosing of everolimus in DLBCL. A large Phase II study in relapsed/refractory DLBCL confirmed the substantial activity (overall response rate: 30%) and good tolerability of everolimus in DLBCL, with thrombocytopenia being the main toxicity. The combination of everolimus and rituximab showed encouraging results (objective response rate: 38%; complete response: 13%), without increasing toxicity. Combination studies of everolimus with novel agents or with immunochemotherapy are underway.

AB - Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell cycle arrest and is synergistic with rituximab. Phase I studies indicated 10 mg daily to be the best dosing of everolimus in DLBCL. A large Phase II study in relapsed/refractory DLBCL confirmed the substantial activity (overall response rate: 30%) and good tolerability of everolimus in DLBCL, with thrombocytopenia being the main toxicity. The combination of everolimus and rituximab showed encouraging results (objective response rate: 38%; complete response: 13%), without increasing toxicity. Combination studies of everolimus with novel agents or with immunochemotherapy are underway.

KW - diffuse large B-cell lymphoma

KW - everolimus

KW - mTOR pathway

KW - rapamycin analogs

UR - http://www.scopus.com/inward/record.url?scp=84923107840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923107840&partnerID=8YFLogxK

U2 - 10.2217/fon.14.264

DO - 10.2217/fon.14.264

M3 - Article

C2 - 25675120

AN - SCOPUS:84923107840

VL - 11

SP - 373

EP - 383

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -